Anna Cäcilia Ingham

Dr. Anna Cäcilia Ingham

Statens Serum Institut, Copenhagen, Denmark
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2021 in Eurosurveillance
Verified
Journal Article
Open access
LELaura Espenhain
Laura Espenhain
TFTjede Funk
Tjede Funk
MOMaria Overvad
Maria Overvad
SESofie Edslev
Sofie Edslev
JFJannik Fonager
Jannik Fonager
LMLuise Müller
Luise Müller
By 9 December 2021, 785 SARS-CoV-2 Omicron variant cases have been identified in Denmark. Most cases were fully (76%) or booster-vaccinated (7.1%); 34 (4.3%) had a previous SARS-CoV-2 infection. The majority of cases with available information reported symptoms (509/666; 76%) and most were infected in Denmark (588/644; 91%). One in five cases cannot be linked to previous cases, indicating widespread community transmission. Nine cases have been hospitalised, one required intensive care and no deaths have been registered.

13 September 2019 in Microbiome
Verified
Journal Article
Open access
PDF file
AIAnna Cäcilia Ingham
Anna Cäcilia Ingham
KKKatrine Kielsen
Katrine Kielsen
MCMalene Skovsted Cilieborg
Malene Skovsted Cilieborg
OLOle Lund
Ole Lund
SHSusan Holmes
Susan Holmes
SPSünje Johanna Pamp
Sünje Johanna Pamp
Background: Increasing evidence reveals the importance of the microbiome in health and disease and inseparable host-microbial dependencies. Host-microbe interactions are highly relevant in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT), i.e., a replacement of the cellular components of the patients’ immune system with that of a foreign donor. HSCT is employed as curative immunotherapy for a number of non-malignant and malignant hematologic conditions, including cancers such as acute lymphoblastic leukemia. The procedure can be accompanied by severe side effects such as infections, acute graft-versus-host disease (aGvHD), and death. Here, we performed a longitudinal analysis of immunological markers, immune reconstitution and gut microbiota composition in relation to clinical outcomes in children undergoing HSCT. Such an analysis could reveal biomarkers, e.g., at the time point prior to HSCT, that in the future could be used to predict which patients are of high risk in relation to side effects and clinical outcomes and guide treatment strategies accordingly.Results: In two multivariate analyses (sparse partial least squares regression and canonical correspondence analysis), we identified three consistent clusters: (1) high concentrations of the antimicrobial peptide human beta-defensin 2 (hBD2) prior to the transplantation in patients with high abundances ofLactobacillaceae, who later developed moderate or severe aGvHD and exhibited high mortality. (2) Rapid reconstitution of NK and B cells in patients with high abundances of obligate anaerobes such asRuminococcaceae, who developed no or mild aGvHD and exhibited low mortality. (3) High inflammation, indicated by high levels of C-reactive protein, in patients with high abundances of facultative anaerobic bacteria such asEnterobacteriaceae.Furthermore, we observed that antibiotic treatment influenced the bacterial community state.Conclusions: We identify multivariate associations between specific microbial taxa, host immune markers, immune cell reconstitution, and clinical outcomes in relation to HSCT. Our findings encourage further investigations into establishing longitudinal surveillance of the intestinal microbiome and relevant immune markers, such as hBD2, in HSCT patients. Profiling of the microbiome may prove useful as a prognostic tool that could help identify patients at risk of poor immune reconstitution and adverse outcomes, such as aGvHD and death, upon HSCT, providing actionable information in guiding precision medicine.

10 March 2022 in Eurosurveillance
Verified
Journal Article
Open access
JFJannik Fonager
Jannik Fonager
MBMarc Bennedbæk
Marc Bennedbæk
PBPeter Bager
Peter Bager
JWJan Wohlfahrt
Jan Wohlfahrt
KEKirsten Maren Ellegaard
Kirsten Maren Ellegaard
MRMorten Rasmussen
Morten Rasmussen
Following emergence of the SARS-CoV-2 variant Omicron in November 2021, the dominant BA.1 sub-lineage was replaced by the BA.2 sub-lineage in Denmark. We analysed the first 2,623 BA.2 cases from 29 November 2021 to 2 January 2022. No epidemiological or clinical differences were found between individuals infected with BA.1 versus BA.2. Phylogenetic analyses showed a geographic east-to-west transmission of BA.2 from the Capital Region with clusters expanding after the Christmas holidays. Mutational analysis shows distinct differences between BA.1 and BA.2.

28 June 2021 in Microbiome
Verified
Journal Article
Open access
PDF file
AIAnna Cäcilia Ingham
Anna Cäcilia Ingham
KKKatrine Kielsen
Katrine Kielsen
HMHanne Mordhorst
Hanne Mordhorst
MIMarianne Ifversen
Marianne Ifversen
FAFrank M. Aarestrup
Frank M. Aarestrup
SPSünje Johanna Pamp
Sünje Johanna Pamp
Background: Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) exhibit changes in their gut microbiota and are experiencing a range of complications, including acute graft-versus-host disease (aGvHD). It is unknown if, when, and under which conditions a re-establishment of microbial and immunological homeostasis occurs. It is also unclear whether microbiota long-term dynamics occur at other body sites than the gut such as the mouth or nose. Moreover, it is not known whether the patients’ microbiota prior to HSCT holds clues to whether the patient would suffer from severe complications subsequent to HSCT. Here, we take a holobiont perspective and performed an integrated host-microbiota analysis of the gut, oral, and nasal microbiota in 29 children undergoing allo-HSCT.Results: The bacterial diversity decreased in the gut, nose, and mouth during the first month and reconstituted again 1–3 months after allo-HSCT. The microbial community composition traversed three phases over 1 year. Distinct taxa discriminated the microbiota temporally at all three body sides, includingEnterococcusspp.,Lactobacillusspp., andBlautiaspp. in the gut. Of note, certain microbial taxa appeared already changed in the patients prior to allo-HSCT as compared with healthy children. Acute GvHD occurring after allo-HSCT could be predicted from the microbiota composition at all three body sites prior to HSCT. The reconstitution of CD4+T cells, TH17, and B cells was associated with distinct taxa of the gut, oral, and nasal microbiota.Conclusions: This study reveals for the first time bacteria in the mouth and nose that may predict aGvHD. Monitoring of the microbiota at different body sites in HSCT patients and particularly through involvement of samples prior to transplantation may be of prognostic value and could assist in guiding personalized treatment strategies. The identification of distinct bacteria that have a potential to predict post-transplant aGvHD might provide opportunities for an improved preventive clinical management, including a modulation of microbiomes. The host-microbiota associations shared between several body sites might also support an implementation of more feasible oral and nasal swab sampling-based analyses. Altogether, the findings suggest that the microbiota and host factors together could provide actionable information to guiding precision medicine.

1 March 2020 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
SPSilvia De Pietri
Silvia De Pietri
AIAnna Cäcilia Ingham
Anna Cäcilia Ingham
TFThomas Leth Frandsen
Thomas Leth Frandsen
MRMathias Rathe
Mathias Rathe
LKLukasz Krych
Lukasz Krych
KMKlaus Müller
Klaus Müller

19 February 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
SESofie Edslev
Sofie Edslev
COCaroline Meyer Olesen
Caroline Meyer Olesen
LNLine Brok Nørreslet
Line Brok Nørreslet
AIAnna Cäcilia Ingham
Anna Cäcilia Ingham
SISøren Iversen
Søren Iversen
PAPaal Skytt Andersen
Paal Skytt Andersen
The skin microbiota of atopic dermatitis (AD) patients is characterized by increased Staphylococcus aureus colonization, which exacerbates disease symptoms and has been linked to reduced bacterial diversity. Skin bacterial communities in AD patients have mostly been described at family and genus levels, while species-level characterization has been limited. In this study, we investigated the role of the bacteria belonging to the Staphylococcus genus using targeted sequencing of the tuf gene with genus-specific primers. We compared staphylococcal communities on lesional and non-lesional skin of AD patients, as well as AD patients with healthy controls, and determined the absolute abundance of bacteria present at each site. We observed that the staphylococcal community, bacterial alpha diversity, and bacterial densities were similar on lesional and non-lesional skin, whereas AD severity was associated with significant changes in staphylococcal composition. Increased S. aureus, Staphylococcus capitis, and Staphylococcus lugdunensis abundances were correlated with increased severity. Conversely, Staphylococcus hominis abundance was negatively correlated with severity. Furthermore, S. hominis relative abundance was reduced on AD skin compared to healthy skin. In conclusion, various staphylococcal species appear to be important for skin health.